New 'Living Drug' trial offers hope for toughest childhood leukemias
NCT ID NCT07464951
Summary
This early-stage study is testing a new type of treatment called CART123 for acute myeloid leukemia (AML) that has come back or hasn't responded to other therapies. It will involve up to 30 children and young adults to see if the treatment is safe and to find the right dose. The study will test the CART123 cells alone and also in combination with an oral medication called ruxolitinib.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.